NEW YORK, May 30 (Reuters) - Schering-Plough Corp's drug Caelyx delayed progression of symptoms among patients with advanced ovarian cancer in a late-stage study, compared with standard treatment, and ...
Final two opinions on medicines made at Ben Venue Laboratories The European Medicines Agency has recommended that the manufacturing processes for the anticancer medicines Caelyx (doxorubicin ...
The U.K. drug price watchdog today gave Johnson & Johnson's ($JNJ) Caelyx the distinction of being one of only two drugs it believes should be funded by the National ...
Kenilworthâ  s Schering-Plough (NYSE: SGP) said Tuesday it has received European Union approval for its Caelyx breast cancer treatment.The drug developer said the approval is for Caelyx as a ...
Patient selection in high-dose chemotherapy trials: relevance in high-risk breast cancer. Seventy-one patients with stage IV breast cancer were treated with Caelyx at doses of 45 to 60 mg/m2 every 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results